Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) Director Joshua S. Boger sold 6,500 shares of the firm’s stock in a transaction that occurred on Wednesday, November 23rd. The shares were sold at an average price of $86.47, for a total value of $562,055.00. Following the completion of the sale, the director now owns 274,725 shares in the company, valued at $23,755,470.75. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) opened at 86.90 on Tuesday. Vertex Pharmaceuticals Inc. has a 12-month low of $73.31 and a 12-month high of $132.81. The company’s market capitalization is $21.55 billion. The firm’s 50-day moving average price is $83.91 and its 200 day moving average price is $89.91.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Tuesday, October 25th. The pharmaceutical company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by $0.02. Vertex Pharmaceuticals had a negative net margin of 13.45% and a negative return on equity of 5.31%. The firm earned $413.78 million during the quarter, compared to analyst estimates of $423.53 million. During the same period last year, the firm earned ($0.13) EPS. Vertex Pharmaceuticals’s quarterly revenue was up 33.6% on a year-over-year basis. On average, equities research analysts expect that Vertex Pharmaceuticals Inc. will post $0.78 EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

ILLEGAL ACTIVITY WARNING: This report was posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this report on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this report can be viewed at https://www.thecerbatgem.com/2016/11/29/vertex-pharmaceuticals-inc-vrtx-director-joshua-s-boger-sells-6500-shares-3.html.

Several institutional investors have recently made changes to their positions in VRTX. Mycio Wealth Partners LLC raised its position in shares of Vertex Pharmaceuticals by 1.5% in the second quarter. Mycio Wealth Partners LLC now owns 1,218 shares of the pharmaceutical company’s stock valued at $105,000 after buying an additional 18 shares during the period. Conning Inc. raised its position in shares of Vertex Pharmaceuticals by 0.3% in the second quarter. Conning Inc. now owns 5,740 shares of the pharmaceutical company’s stock valued at $494,000 after buying an additional 20 shares during the period. Municipal Employees Retirement System of Michigan raised its position in shares of Vertex Pharmaceuticals by 0.3% in the third quarter. Municipal Employees Retirement System of Michigan now owns 7,820 shares of the pharmaceutical company’s stock valued at $682,000 after buying an additional 20 shares during the period. Northwestern Mutual Investment Management Company LLC raised its position in shares of Vertex Pharmaceuticals by 0.3% in the second quarter. Northwestern Mutual Investment Management Company LLC now owns 9,435 shares of the pharmaceutical company’s stock valued at $812,000 after buying an additional 28 shares during the period. Finally, Fisher Asset Management LLC raised its position in shares of Vertex Pharmaceuticals by 1.1% in the third quarter. Fisher Asset Management LLC now owns 5,168 shares of the pharmaceutical company’s stock valued at $451,000 after buying an additional 56 shares during the period. 95.39% of the stock is owned by institutional investors.

Several research firms recently commented on VRTX. Vetr upgraded Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and set a $87.67 target price on the stock in a research report on Monday, November 21st. Janney Montgomery Scott assumed coverage on Vertex Pharmaceuticals in a research report on Thursday, November 17th. They issued a “neutral” rating and a $98.00 target price on the stock. William Blair lowered Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $105.00 to $81.00 in a research note on Tuesday, November 1st. Zacks Investment Research raised Vertex Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, October 31st. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $108.00 price target (down from $109.00) on shares of Vertex Pharmaceuticals in a research note on Friday, October 28th. Sixteen investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Vertex Pharmaceuticals has a consensus rating of “Hold” and an average price target of $108.13.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

5 Day Chart for NASDAQ:VRTX

Receive News & Stock Ratings for Vertex Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.